Beyond First Line Therapy Phase IIb trial of pemigatinib in combination with atezolizumab and bevacizumab for treatment of advanced cholangiocarcinoma with FGFR2 fusion LEARN MORE
Beyond First Line Therapy A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in Advanced Refractory Solid Tumors LEARN MORE
Chemotherapy Herizon BTC-302 An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard of care therapy alone for advanced HER2 positive biliary tract cancer LEARN MORE
Beyond First Line Therapy A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) LEARN MORE
Beyond First Line Therapy A Phase 2 study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements LEARN MORE
Chemotherapy Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases LEARN MORE
Chemotherapy A single arm phase 2 study of Y-90 SIRT in combination with durvalumab (MEDI 4736) and gemcitabine/cisplatin in locally advanced, unresectable or metastatic intrahepatic cholangiocarcinoma LEARN MORE
Targeted Therapy A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations LEARN MORE
Other Novel Therapies Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer LEARN MORE
